Sign up to save your podcasts
Or
Share April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Next-Generation Treatments for Moderate-to-Severe Plaque Psoriasis: What's New in TYK2
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Next-Generation Treatments for Moderate-to-Severe Plaque Psoriasis: What's New in TYK2
Please visit answersincme.com/JCY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the current and potential clinical impact of TYK2 inhibitors. Upon completion of this activity, participants should be better able to: Contrast the clinical implications of selective TYK2 inhibition versus pan-JAK inhibition in the treatment of moderate-to-severe plaque psoriasis; Interpret the clinical evidence for next-generation TYK2 inhibitors in patients with moderate-to-severe plaque psoriasis; and Integrate TYK2 inhibitors into clinical practice as they become available for patients with moderate-to-severe plaque psoriasis.
View all episodes
By Answers in CME
5
33 ratings
Please visit answersincme.com/JCY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the current and potential clinical impact of TYK2 inhibitors. Upon completion of this activity, participants should be better able to: Contrast the clinical implications of selective TYK2 inhibition versus pan-JAK inhibition in the treatment of moderate-to-severe plaque psoriasis; Interpret the clinical evidence for next-generation TYK2 inhibitors in patients with moderate-to-severe plaque psoriasis; and Integrate TYK2 inhibitors into clinical practice as they become available for patients with moderate-to-severe plaque psoriasis.